Current therapeutic strategies are mainly designed to induce relaxation of the pulmonary arteries, not to improve vascular remodeling that characterizes PAH. Will newer agents remodel the vasculature?
Climate change is a key driver of the accelerating environmental change affecting populations around the world. Many of these changes and our response to them can affect respiratory health.
An ideal biomarker for bacterial pulmonary infections should allow a rapid diagnosis, have a prognostic value and maybe facilitate therapeutic decision making.